Search

Displaying results 8751 - 8760 of 10000 in total
  1. Drug

    Solabegron

    go.drugbank.com/drugs/DB06190
    Investigational

    Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive bladder and irritable bowel syndrome.

    Categories: Adrenergic beta-3 Receptor Agonists
  2. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. … In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC.

  3. Drug

    Tolperisone

    go.drugbank.com/drugs/DB06264
    Investigational

    Tolperisone is an oral, centrally acting muscle relaxant. Its precise mechanism is not completely understood, though it blocks sodium and calcium channels. … Based on existing clinical data, Tolperisone is not sedating and does not interact with alcohol.

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-Ring
  4. Drug

    Levocetirizine

    go.drugbank.com/drugs/DB06282
    ApprovedInvestigational

    Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. … [L7694] Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine.[L7694] Levocetirizine was granted FDA approval in 1995.[L7694]

    Mixtures: ANTISS® D, ANTISS® DCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  5. Drug

    Fiboflapon

    go.drugbank.com/drugs/DB06346
    Investigational

    Categories: Heterocyclic Compounds, 2-Ring
  6. Drug

    Elacestrant

    go.drugbank.com/drugs/DB06374
    ApprovedInvestigational

    Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist. … of a SERD represents a therapeutic approach for the treatment of endocrine-resistant breast cancers.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: (2R)-2-(2-(ethyl-((4-(2-(ethylamino)ethyl)phenyl)methyl)amino)-4-methoxy-phenyl)tetralin-6-ol, (6R)-6-(2-(ethyl((4-(2- (ethylamino)ethyl)phenyl)methyl)amino)-4-methoxyphenyl)- 5,6,7,8-tetrahydronaphthalen-2-ol
  7. Drug

    Talnetant

    go.drugbank.com/drugs/DB06429
    Investigational

    Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential

    Categories: Heterocyclic Compounds, 2-Ring, Receptors, Neurokinin-3, antagonists & inhibitors
  8. Drug

    Enzastaurin

    go.drugbank.com/drugs/DB06486
    Investigational

    Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.

    Categories: Heterocyclic Compounds, 2-Ring
  9. Drug

    R-1487

    go.drugbank.com/drugs/DB06518
    Experimental

    Salts: R-1487 hydrochlorideCategories: Heterocyclic Compounds, 1-Ring
  10. Drug

    Mitemcinal

    go.drugbank.com/drugs/DB06587
    Investigational

    Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors